Working… Menu

The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV) (STAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03159884
Recruitment Status : Unknown
Verified February 2017 by Chengdu Kanghong Biotech Co., Ltd..
Recruitment status was:  Recruiting
First Posted : May 19, 2017
Last Update Posted : July 19, 2017
Information provided by (Responsible Party):
Chengdu Kanghong Biotech Co., Ltd.

Brief Summary:
To assess the efficacy of intravitreal injection of 0.5 mg conbercept in patients with polypoidal choroidal vasculopathy (PCV) and explore the optimal route of administration.

Condition or disease Intervention/treatment Phase
Polypoidal Choroidal Vasculopathy (PCV) Drug: Conbercept Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)
Study Start Date : October 2015
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 3+Q12W
The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, followed by every 12 weeks. If the subject meets the "additional medication criteria" in 12 weeks during treatment, additional injection can be given;
Drug: Conbercept
Experimental: 3+TAE
The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, then the researcher will determine the next follow-up visit time/treatment interval based on results of each follow-up assessment as per the "treatment-extended dosing criteria". When the follow-up/treatment interval of the subject is extended to 12 weeks, additional safety follow-up visit can be arranged if any suspicious active lesion is deemed by the researcher; additional injection can be given if the result of safety follow-up assessment meets the "extra dosing criteria".
Drug: Conbercept

Primary Outcome Measures :
  1. Change of Best Corrected Visual Acuity [ Time Frame: Baseline, 12th and 48th week ]
    The investigators will use the ETARS Chart which is international standard to measure the vision ability of participants.Best corrected visual is the number of letters which the participants can read on the ETARS Chart ,all procedure should be done according to SOP.The BCVA of 12th week and 48th week will be compared with the base line(pre-treatment).

Secondary Outcome Measures :
  1. Central Retinal Thickness (CRT) [ Time Frame: week 48 ]
    To observe pre- and posttreatment changes in CRT on OCT

  2. Change of Macular Retinal Thickness (MRT) [ Time Frame: week 48 ]
    To observe pre-and posttreatment changes on OCT;

  3. Volume and Thickness of Retinal Pigment Epithelial Detachment (PED) [ Time Frame: week 48 ]
    To observe pre- and posttreatment changes in volume and thickness of PED on OCT;

  4. Area and Regression of Polypoidal Lesion [ Time Frame: week 48 ]
    To observe pre- and posttreatment changes in area and regression of polypoidal lesion on ICGA

  5. Size of Retinal Hemorrhages [ Time Frame: week 48 ]
    To observe pre- and posttreatment changes in size of retinal hemorrhages on CFP

  6. Area of Branching Vascular Network [ Time Frame: week 48 ]
    To observe pre- and posttreatment changes in area of BVN on ICGA

  7. Frequency of Administration [ Time Frame: up to 48 weeks ]
    Refers to the average frequency of administration for both groups of subjects during the study.

  8. Incidence of adverse events (AEs) and reactions [ Time Frame: up to 48 weeks ]
  9. Ophthalmic examination [ Time Frame: up to 48 weeks ]
    Ophthalmic examination include corneal、vitreous body、anterior chamber、iris、retina、disc、Macular 、drusen、PED examination Investigator will check whether the parts above is normal. Measurement for summarizing the data : Number of patients with different conditions of each part.

  10. General symptoms and vital signs [ Time Frame: up to 48 weeks ]
    Number of participants with abnormal symptoms or vital signs.

  11. Number of participants with adverse events as assessed by laboratory results [ Time Frame: up to 48 weeks ]
    Laboratory results include Blood routine 、Blood biochemistry、Coagulation function 、Urine routine 、Urinary pregnancy .

  12. Number of participants with treatment-related adverse events as assessed by other tests. [ Time Frame: up to 48 weeks. ]
    Other tests indicated that which is not contained in the study done by the participants .

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient who has signed an informed consent form and is inclined to be followed up within the time stipulated in the trial;
  • Patient with wet AMD aged ≥ 45, of either sex;
  • The eye of interest must meet the following requirements:

    1. BCVA is at least 19 and at most 83 alphabets (equivalent to a visual acuity of 20/25 to 20/400 for the Snellen Eye Chart);
    2. Patient has been diagnosed with active PCV on ICGA (confirmed by the third-party radiodiagnosis center); The diagnostic criteria for "active" PCV on ICGA are as follows: image indicates polypoid lesions as typical nodular high fluorescein area (observed stereoscopically) and also depicts one of the following angiographic findings: 1) nodular lesions surrounded by the weak halo; 2) nodular lesions nourished by abnormal vascular beds; and 3) nodular pulsation on dynamic ICGA;
    3. In case of the eye of interest complicated with subretinal hemorrhage or hemorrhage under the pigment epithelium, the range of hemorrhage should not be beyond the upper and lower vascular arcades in the macular area, and the total thickness of the central fovea (i.e., the thickness between the apex of the central fovea and the choriocapillary layer) is no more than 600 µm;
    4. Neither ocular media opacity nor miosis is noted to influence the fundus examination.
  • Subject with the BCVA of no less than 19 alphabets for his/her eye of non-interest (equivalent to a visual acuity of 20/400 for the Snellen Eye Chart).

Note: Each subject in the study can include only one eye of interest; the eye of interest is determined by the researcher from a medical point of view if both eyes of the subject meet the inclusion criteria.

Exclusion Criteria:

  • Subfoveal fibrous tissues are present in the eye of interest on CFP and OCT;
  • Researcher judges that existing or previous ocular diseases in the eye of interest influence the macular detection or the central visual acuity (CNV secondary to diseases other than AMD, diabetic retinopathy, uveitis, angioid streaks, pathologic myopia, retinal pigment epithelium (RPE) tears, macular holes, any retinal vasculopathy, vein occlusion, amblyopia, retinal inflammatory diseases, central serous choroidopathy, previous or existing retinal detachment, macular edema, anterior ischemic optic neuropathy, pseudovitelliform macular degeneration, vitreomacular traction syndrome, rhegmatogenous retinal detachment, generalized choroidal atrophy, and optic atrophy (pale));
  • There is any history of vitreous hemorrhage three months before screening;
  • The eye of interest has received any drug therapy for AMD (e.g., pegaptanib sodium or steroids) or any anti-VEGF therapy (e.g., ranibizumab or bevacizumab);
  • The eye of interest has received verteporfin-photodynamic therapy (PDT) and foveal laser-induced thermal therapy (including subfoveal or paracentral photocoagulation, grid photocoagulation, transpupillary thermotherapy (TTT) and pan-retinal photocoagulation);
  • The eye of interest has received intra- or periocular surgery (including parafoveal laser photocoagulation treatment, cataract surgery, and YAG laser posterior capsulotomy) within three months, except eyelid surgery having no effect on intravitreal injection (but eyelid surgery could not be performed one month before medication);
  • The eye of interest has received the following ophthalmic operations, including vitrectomy, macular translocation, glaucoma surgery, laser photocoagulation and pan-retinal photocoagulation, as well as other submacular surgeries or other surgeries for CNV;
  • The eye of interest has received keratoplasty;
  • Either eye has active eye infection (e.g., blepharitis, infective conjunctivitis, keratitis, scleritis, and endophthalmitis) or recurrent infection, or the eye of interest has been infected 30 days before screening;
  • Patient has either previous or existing uncontrollable glaucoma (defined as IOP remaining at above 25 mmHg after anti-glaucoma treatment), or the cup-to-disc ratio of the eye of interest is above 0.8 due to severe glaucoma, or the eye of interest has received glaucoma filtration surgery;
  • No ruptured lens (excluding pseudophakic) or posterior lens capsule (except YAG laser posterior capsulotomy after intraocular lens implantation);
  • Patient needs to receive cataract surgery three months after enrollment (i.e., the researcher judges that BCVA may decrease by no less than 10 alphabets for the subject if the surgery is not performed);
  • The eye of interest has ocular tumor;
  • There is a history of systemic use of anti-VEGF agent(s) in six months;
  • Patient has a history of anaphylaxis and allergy to fluorescein sodium and indocyanine green, and of allergy to protein products for diagnosis or treatment, and is allergic to no less than two drugs and/or non-drug factors, or suffers from allergic diseases now;
  • Diabetics with uncontrolled blood glucose (fasting blood glucose ≥ 7.0 mmol/L or 2hPBG ≥ 11.1 mmol/L) and/or complicated with diabetic retinopathy;
  • Patient has had a surgical history one month before enrollment, and/or has unhealed wounds, ulcers and fractures at present;
  • Patient has infectious diseases required oral, intramuscular or intravenous administration at present;
  • Patient has a history of myocardial and/or cerebral infarction(s) within 6 months before screening, has received stenting and depends on such anticoagulants as warfarin and aspirin;
  • Patient chronically uses and cannot discontinue to use such anticoagulants as aspirin, clopidogrel and warfarin;
  • Patient has active and disseminated intravascular coagulation and distinct bleeding tendency three months before screening;
  • Hyperpietics with poor blood pressure control (defined as blood pressure remaining at ≥ 150/95 mmHg after antihypertensives therapy);
  • Patient is diagnosed with systemic immune disease (e.g., ankylosing spondylitis, systemic lupus erythematosus, and Behcet's disease) or has any uncontrollable clinical problem (e.g., AIDS, malignancies, active hepatitis, renal failure, severe mental, neurological, cardiovascular and respiratory diseases);
  • Patient has previously used drugs which may possibly cause renal toxicity, including chloroquine, hydroxychloroquine, phenothiazines, chlorpromazine, thioridazine, fluphenazine, perphenazine, and trifluoperazine;
  • Patient does not take effective contraceptive measures; Note: The following conditions are not included in the exclusion range.

    1. Amenorrhea for 12 months under the natural condition, or amenorrhea for 6 months under the natural condition and the serum FSH level of > 40 mIU/ml;
    2. Six weeks after bilateral ovariectomy with/without hysterectomy;
    3. Use of the following one or more acceptable contraceptions:

      • Sterilization (for males, with bilateral vasoligation and vasectomy)
      • Hormonal contraception (implantable, patchable, oral)
      • Intrauterine device and dural barrier method
    4. Ability to take reliable contraceptive measures over the study period and hold on to 30 days after study drug withdrawal (unacceptable contraceptive methods include: periodic continence - according to the calendar and ovulatory phase, body thermometry, post-ovulatory method, and coitus interruptus).
  • Pregnant women (in this trial pregnancy is defined as positive U-HCG) and breastfeeding mothers;
  • Patient has participated in any drug (not including vitamins and minerals) clinical trial three months before screening (if the study drug has a long half-life, i.e., its five half-lives exceed three months, then it is deemed as five half-lives); Those whom the reseacher deems necessary to exclude.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03159884

Layout table for location contacts
Contact: xiaoxin Li

Layout table for location information
Beijing Hospital Recruiting
Beijing, China
Contact: Hong Dai         
Beijing Shijitan Hoospital.Cmu Recruiting
Beijing, China
Contact: Lin Xiao         
Beijing Tongren Hospital,Cmu Recruiting
Beijing, China
Contact: Feng Zhang         
Chinese Pla General Hospital Recruiting
Beijing, China
Contact: Zhaohui Li         
Peking Union Medical College Hospital Recruiting
Beijing, China
Contact: Youxing Cheng         
Peking University First Hospital Recruiting
Beijing, China
Contact: Liu Yang         
Peking University People'S Hospital Recruiting
Beijing, China
Contact: xiaoxin Li         
Beijing, China
Contact: Hongliang Dou         
The Scond Xiangya Hospital of Central South University Recruiting
Changsha, China
Contact: Luosheng Tang         
Xiangya Hospital Central South University Recruiting
Changsha, China
Contact: Huizuo Xu         
General Hospial og Guangzhou Military Command of PLA Recruiting
Guangzhou, China
Contact: Xiulan Zou         
ZhongShan Ophthalmic Center,Sun Yat-sen University Recruiting
Guangzhou, China
Contact: Chenjin Jin         
Hainan Eye Hospital of Zhongshan Ophthalmic Center, Sun Yat-sen University Recruiting
Hainan, China
Contact: Wangling Cheng         
Hebei Eye Hospital Recruiting
Hebei, China
Contact: Minlian Zhang         
The Second Hospital of Hebei Medical University Recruiting
Hebei, China
Contact: Jingxue Ma         
Henan Province People's Hospital Recruiting
Henan, China
Contact: Ke Fan         
The Second Hospital of Jilin University Recruiting
Jilin, China
Contact: Guanfang Su         
Lanzhou University Second Hospital Recruiting
Lanzhou, China
Contact: Wenfang Zhang         
Affiliated Eye Hospital of Nanchang University Recruiting
Nanchang, China
Contact: Jingling Yi         
The First Affiliated Hospital of Nanchang University Recruiting
Nanchang, China
Contact: Qiong Zhou         
Nanjing General Hospital Recruiting
Nanjing, China
Contact: Zhengping Huang         
The First Affiliated Hospital With Nanjing Medical University Recruiting
Nanjing, China
Contact: Qinghui Lui         
Ningxia Peple'S Hospital Recruiting
Ningxia, China
Contact: Shaoping Ha         
Eye&Ent Hospital of Fudan University Recruiting
Shanghai, China
Contact: Yongjing Zhang         
Renji Hospital Shanghai Jiaotong University School of Medicine Recruiting
Shanghai, China
Contact: Lin Liu         
Shanghai General Hospital Recruiting
Shanghai, China
Contact: Suqing Yu         
Stu/Cuhk Joint Shantou International Eye Center Recruiting
Shantou, China
Contact: Weiqi Cheng         
Shanxi Eye Hospital Recruiting
Shanxi, China
Contact: Yading Jia         
Shenzhen Eye Hospital Recruiting
Shenzhen, China
Contact: Qinshan Cheng         
Tianjin Medical University Eye Hospital Recruiting
Tianjin, China
Contact: Xiaorong Li         
The Eye Hospital of Wmu Zhejiang Eye Hospital Recruiting
Wenzhou, China
Contact: Xiaoling Liu         
Renmin Hospital of Wuhan University Recruiting
Wuhan, China
Contact: Yiqiao Xing         
The Chinese people's liberation army 474 hospital Recruiting
Wulumuqi, China
Contact: Yun Xiao         
Xiamen Eye Centre of Xiamen University Recruiting
Xiamen, China
Contact: Guoji Wu         
The Second Affiliated Hospital Zhejiang University School of Medicine Recruiting
Zhejiang, China
Contact: Ke Yao         
Sponsors and Collaborators
Chengdu Kanghong Biotech Co., Ltd.

Layout table for additonal information
Responsible Party: Chengdu Kanghong Biotech Co., Ltd. Identifier: NCT03159884     History of Changes
Other Study ID Numbers: KH902-ST-CRP-2.0
First Posted: May 19, 2017    Key Record Dates
Last Update Posted: July 19, 2017
Last Verified: February 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases